Log in

NASDAQ:TCDA - Tricida Stock Price, Forecast & News

+1.99 (+4.97 %)
(As of 12/8/2019 04:10 AM ET)
Today's Range
Now: $42.06
50-Day Range
MA: $38.13
52-Week Range
Now: $42.06
Volume353,751 shs
Average Volume273,834 shs
Market Capitalization$2.09 billion
P/E RatioN/A
Dividend YieldN/A
Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:TCDA



Sales & Book Value

Annual SalesN/A
Book Value$4.62 per share


Net Income$-102,810,000.00


Market Cap$2.09 billion
Next Earnings Date3/26/2020 (Estimated)
OptionableNot Optionable

Receive TCDA News and Ratings via Email

Sign-up to receive the latest news and ratings for TCDA and its competitors with MarketBeat's FREE daily newsletter.

Tricida (NASDAQ:TCDA) Frequently Asked Questions

What is Tricida's stock symbol?

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

How were Tricida's earnings last quarter?

Tricida Inc (NASDAQ:TCDA) announced its quarterly earnings results on Thursday, November, 14th. The company reported ($0.89) EPS for the quarter, meeting analysts' consensus estimates of ($0.89). View Tricida's Earnings History.

When is Tricida's next earnings date?

Tricida is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Tricida.

What price target have analysts set for TCDA?

3 brokerages have issued 12-month target prices for Tricida's shares. Their forecasts range from $48.00 to $58.00. On average, they anticipate Tricida's stock price to reach $51.50 in the next year. This suggests a possible upside of 22.4% from the stock's current price. View Analyst Price Targets for Tricida.

What is the consensus analysts' recommendation for Tricida?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tricida.

Has Tricida been receiving favorable news coverage?

News articles about TCDA stock have trended somewhat positive this week, InfoTrie reports. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Tricida earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Tricida.

Are investors shorting Tricida?

Tricida saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 3,590,000 shares, an increase of 5.9% from the October 31st total of 3,390,000 shares. Based on an average trading volume of 199,400 shares, the days-to-cover ratio is presently 18.0 days. Currently, 10.4% of the company's shares are short sold. View Tricida's Current Options Chain.

Who are some of Tricida's key competitors?

What other stocks do shareholders of Tricida own?

Who are Tricida's key executives?

Tricida's management team includes the folowing people:
  • Dr. Gerrit Klaerner, Founder, Pres, CEO & Exec. Director (Age 48)
  • Mr. Geoffrey M. Parker, CFO & Sr. VP (Age 54)
  • Dr. Dawn Parsell Ph.D., Sr. VP of Clinical Devel. (Age 57)
  • Steffen Pietzke, VP of Fin. & Chief Accounting Officer
  • Dr. Wilhelm Stahl, CTO & Sr. VP (Age 59)

When did Tricida IPO?

(TCDA) raised $175 million in an IPO on Thursday, June 28th 2018. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen acted as the underwriters for the IPO.

Who are Tricida's major shareholders?

Tricida's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Redmile Group LLC (4.19%), Great Point Partners LLC (1.18%), State Street Corp (1.01%), Massachusetts Financial Services Co. MA (0.64%), Point72 Asset Management L.P. (0.57%) and California Public Employees Retirement System (0.09%). Company insiders that own Tricida stock include Beek Jeroen B Van, Brian M Isern, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Geoffrey M Parker, Gerrit Klaerner, Klaus R Dr Veitinger, Longitude Capital Partners Ii,, Orbimed Advisors Llc, Robert J Alpern, Sandra I Coufal, Sibling Capital Fund Ii-A LP, Steffen Pietzke and Wilhelm Stahl. View Institutional Ownership Trends for Tricida.

Which major investors are selling Tricida stock?

TCDA stock was sold by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Millennium Management LLC, Massachusetts Financial Services Co. MA and Rhumbline Advisers. Company insiders that have sold Tricida company stock in the last year include Brian M Isern, Claire Lockey, Dawn Parsell Otto, Gerrit Klaerner, Klaus R Dr Veitinger, Robert J Alpern, Sandra I Coufal, Sibling Capital Fund Ii-A LP and Wilhelm Stahl. View Insider Buying and Selling for Tricida.

Which major investors are buying Tricida stock?

TCDA stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Redmile Group LLC, California Public Employees Retirement System, State Street Corp, Barclays PLC, Nisa Investment Advisors LLC, Tower Research Capital LLC TRC and Metropolitan Life Insurance Co NY. Company insiders that have bought Tricida stock in the last two years include Beek Jeroen B Van, Edward J Hejlek, Geoffrey M Parker, Longitude Capital Partners Ii,, Orbimed Advisors Llc, Sandra I Coufal and Steffen Pietzke. View Insider Buying and Selling for Tricida.

How do I buy shares of Tricida?

Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Tricida's stock price today?

One share of TCDA stock can currently be purchased for approximately $42.06.

How big of a company is Tricida?

Tricida has a market capitalization of $2.09 billion. The company earns $-102,810,000.00 in net income (profit) each year or ($4.64) on an earnings per share basis. Tricida employs 76 workers across the globe.View Additional Information About Tricida.

What is Tricida's official website?

The official website for Tricida is http://www.tricida.com/.

How can I contact Tricida?

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected]

MarketBeat Community Rating for Tricida (NASDAQ TCDA)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  86 (Vote Outperform)
Underperform Votes:  125 (Vote Underperform)
Total Votes:  211
MarketBeat's community ratings are surveys of what our community members think about Tricida and other stocks. Vote "Outperform" if you believe TCDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TCDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Featured Article: Dogs of the Dow

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel